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Abstract 
Infection with Bordetella bronchiseptica (Bb), a pathogen involved in canine infectious respiratory disease complex, 
can be confirmed using culture or qPCR. Studies about the canine lung microbiota (LM) are recent, sparse, and 
only one paper has been published in canine lung infection. In this study, we aimed to compare the LM between 
Bb infected and healthy dogs, and to correlate sequencing with culture and qPCR results. Twenty Bb infected dogs 
diagnosed either by qPCR and/or culture and 4 healthy dogs were included. qPCR for Mycoplasma cynos (Mc) were 
also available in 18 diseased and all healthy dogs. Sequencing results, obtained from bronchoalveolar lavage fluid 
after DNA extraction, PCR targeting the V1–V3 region of the 16S rDNA and sequencing, showed the presence of Bb 
in all diseased dogs, about half being co‑infected with Mc. In diseased compared with healthy dogs, the β‑diversity 
changed (P = 0.0024); bacterial richness and α‑diversity were lower (P = 0.012 and 0.0061), and bacterial load higher 
(P = 0.004). Bb qPCR classes and culture results correlated with the abundance of Bb (r = 0.71, P < 0.001 and r = 0.70, 
P = 0.0022). Mc qPCR classes also correlated with the abundance of Mc (r = 0.73, P < 0.001). Bb infection induced lung 
dysbiosis, characterized by high bacterial load, low richness and diversity and increased abundance of Bb, compared 
with healthy dogs. Sequencing results highly correlate with qPCR and culture results showing that sequencing can be 
reliable to identify microorganisms involved in lung infectious diseases.
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is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
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zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Bordetella bronchiseptica, a Gram-negative, aerobic, coc-
cobacillus, is regarded as one of the principal pathogens 
involved in canine infectious respiratory disease com-
plex (CIRD-C) [1–4]. Its prevalence in dogs with infec-
tious respiratory diseases ranges from 5.2 to 78.7% [2, 
4–6]. According to the taxonomical classification, the 
bacterium B. bronchiseptica belongs to the Proteobacte-
ria phylum, the Alcaligenaceae family and the Bordetella 
genus [7]. CIRD-C or formerly “kennel cough” is consid-
ered as one of the most common infectious diseases in 
dogs worldwide despite vaccination, and affects mostly 
young and kennel dogs [8]. Viruses such as canine ade-
novirus, canine distemper virus, canine parainfluenza 
virus, canine respiratory coronavirus, pneumovirus and 
influenza A virus and bacteria other than B. bronchisep-
tica such as Mycoplasma cynos and Streptococcus equi 
subsp. zooepidermicus are primary infectious agents 
involved in the complex [4, 8]. Because of the numer-
ous infectious etiologies as well as possible co-infections, 
clinical signs of CIRD-C are highly variable and difficult 
to predict ranging from mild illness to severe pneumo-
nia or death [8]. Among the bacteria, Mycoplasma cynos, 
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a Gram-negative organism is considered as an emerg-
ing bacterium in CIRD-C [4, 9]. This bacterium belongs 
to the Tenericutes phylum, the Mycoplasmataceae fam-
ily and the Mycoplasma genus [10]. The diagnosis of B. 
bronchiseptica infection can be confirmed either by cul-
ture or by specific quantitative polymerase chain reaction 
(qPCR) on various samples including bronchoalveolar 
lavage fluid (BALF). The bacteria can also be observed on 
cytological preparations, adhering to the top of the cilia 
of respiratory epithelial cells [1]. The treatment against 
B. bronchiseptica can be challenging as the bacterium is 
localized at the top of the cilia, can adopt a biofilm life-
style and may drive an immunosuppressive response 
[11–15]. In such cases, classical oral or parenteral anti-
microbial drug may not be sufficient even if in vitro sus-
ceptibility is shown [16]. Recently, it has been shown that 
gentamycin nebulization was helpful to achieve thera-
peutic concentration on the apical surface of bronchial 
epithelium, mostly when classical antimicrobial drugs 
failed to be curative [17–19].
The 16S rDNA amplicon sequencing is a technique 
less sensitive than a qPCR but which allows rapid and 
accurate identification of all the bacteria composing the 
microbiota, which refers to the global microbial popula-
tion of an area, including rare, unknown, slow-growing 
and unculturable bacteria [20–23]. Moreover, this tech-
nique allows to highlight the complexity of the microbial 
populations and their alterations in disease processes 
[20, 23]. In man, the 16S rDNA amplicon sequencing is 
increasingly being used in clinical contexts such as in 
acute pneumonia. Acute pneumonia is considered as an 
abrupt, emergent phenomenon with the predominance 
of specific taxonomic groups, low microbial diversity and 
high bacterial load [24–26]. Studies in acute pneumonia 
indicate that the 16S rDNA sequencing improves the 
microbiological yield and could help to guide antimicro-
bial therapy [20, 27]. In dogs, the lung microbiota (LM) 
has only been studied in bacterial secondary or commu-
nity-acquired pneumonia (CAP) and only few data are 
available in experimental healthy beagles [28–30] and 
healthy dogs from other breeds [31]. In dogs with pneu-
monia, a dysbiosis of the LM was observed with the loss 
of bacteria found in health and the domination, mostly 
in CAP, of one or two bacteria [30]. Moreover a good 
agreement was found between the results of 16S rDNA 
amplicon sequencing and culture, although some dis-
crepancies concerning the number of unique taxa identi-
fied and presence or absence of predominating taxa were 
noticed [30]. Results suggest that the 16S rDNA amplicon 
sequencing could be useful for causal bacteria detection 
in parallel with culture, mostly if culture is negative [30].
The aims of this study were to analyze the LM in 
a series of cases with B. bronchiseptica infection in 
comparison with healthy dogs and to correlate results of 




Client-owned dogs referred to the veterinary hospital 
of the University of Liège, between January 2014 and 
December 2018, with a diagnosis of B. bronchiseptica 
infection, were recruited. Infection with B. bronchisep-
tica was confirmed by either positive culture (> 104 col-
ony forming unit/mL), or positive qPCR, or both, on 
BALF samples and by the resolution of the clinical signs 
after adapted antimicrobial drug administration. Another 
inclusion criterion concerned the availability of BALF 
banked at −80  °C, for LM analysis. Data were collected 
from the medical records and included signalment, his-
tory, clinical signs, thoracic radiography, bronchoscopy 
findings and BALF analysis results, as well as culture and 
qPCR results.
BALF samples from healthy dogs involved in an inde-
pendent study analyzing the effect of the type of breed 
on the LM composition were also used. Those samples 
were obtained according to a protocol approved by the 
Ethical Committee of the University of Liège (proto-
col #1435) and after the owner consent. Healthy sta-
tus was confirmed based on a complete history without 
abnormalities, normal physical examination, blood work 
(hematology and biochemistry), bronchoscopy and BALF 
analysis (gross appearance and cell counts). Healthy dogs 
did not receive any kind of antimicrobial drugs or probi-
otics for the year preceding the study.
BALF collection and processing
Bronchoscopy, bronchoalveolar lavage (BAL) procedure, 
and BALF processing and analysis were performed as 
already described [1, 29]. Briefly, dogs were anesthetized 
using various protocols at the discretion of a board-cer-
tified anesthesiologist. A flexible pediatric endoscope 
(FUJINON© Paediatric Video-Bronchoscope EB-530S) 
cleaned and disinfected before each use was inserted into 
the trachea until the extremity was wedged into the bron-
chi. Three to four mL/kg of sterile saline solution (NaCl 
0.9%) divided into three aliquots were instilled into at 
least two different lung lobes, followed by aspiration by 
gentle suction. The recovered BALF was pooled. Before 
each BAL in dogs, a procedural control specimen (PCS) 
was obtained by injection and aspiration of 10 mL of ster-
ile saline solution (NaCl 0.9%) through the bronchoscope.
Just after BALF collection, total (TCC) and differen-
tial cells counts (DCC) were determined using respec-
tively a hemocytometer and a cytospin preparation 
(centrifugation at 221  g, for 4  min at 20  °C, Thermo 
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Shandon Cytospin©4), by counting a total of 200 cells at 
high power field. Part of the crude BALF was promptly 
stored in cryotubes at −80  °C for the microbiota analy-
sis and the remaining BALF was centrifuged at 3500 × g 
15 min at 4  °C and divided into pellets and supernatant 
also stored separately at −80 °C. The PCSs were stored in 
cryotubes at −80 °C without processing.
Culture
Culture from crude fresh BALF samples were per-
formed for aerobic bacteria detection. Cultures were 
conducted at 35  °C on several agar plates (Chapman’s, 
Mac Conkey’s, CAN and TSS agar). Standard biochemi-
cal methods were used to identified the bacteria (Synlab 
Laboratories, Liège, Belgium). Due to challenging growth 
requirements and as it is not classically performed in 
clinic, Mycoplasma sp. was not cultured. BALF samples 
from healthy dogs were not submitted to conventional 
bacterial culture.
B. bronchiseptica and M. cynos qPCR
In diseased dogs, qPCR targeting B. bronchiseptica and 
M. cynos were performed either on crude fresh BALF 
when performed immediately after the BAL procedure or 
on pellet and crude frozen BALF when performed later. 
In healthy dogs, qPCRs were performed on frozen pel-
let BALF (Department of Veterinary Pathology, Liège, 
Belgium).
DNA was extracted from samples using the Nucleo-
Mag Vet kit (Macherey-Nägel GmbH & Co. KG, Düren, 
Germany) according to the protocol provided by the 
manufacturer. Total DNA quantity and purity were meas-
ured after extraction using the ND-1000 spectropho-
tometer (NanoDrop ND-1000, Isogen, De Meern, The 
Netherlands).
For B. bronchiseptica and M. cynos detection, duplicate 
qPCR reactions (20 µL) included 2 µL of DNA template, 
10  µL Luna Universal Probe qPCR Master Mix (Bioké, 
The Netherlands), 6 µL of water and 2  µL of the prim-
ers mix. For B. bronchiseptica, the primers mix contained 
20 µL of the forward primer (5′-ACT ATA CGT CGG GAA 
ATC TGT TTG -3′) and the reverse primer (5′-CGT TGT 
CGG CTT TCG TCT G -3′) at 10  µM and 10  µL of the 
probe (5′-FAM-CGG GCC GAT AGT CAG GGC GTAG-
BHQ1-3′) at 10 µM [32]. The cycling conditions started 
with an initial denaturation step at 95  °C for 10  min, 
followed by 45 cycles of denaturation at 95  °C for 30  s, 
primer annealing at 55 °C for 20 s and elongation at 72 °C 
for 1 min. For M. cynos, the primers mix contained 20 µL 
of the forward primer (5′-GTG GGG ATG GAT TAC CTC 
CT-3′) and the reverse primer (5′-GAT ACA TAA ACA 
CAA CAT TAT AAT ATTG-3′) at 10 µM and 10 µL of the 
probe (5′-TCT ACG GAG TAC AAG TTA CAA TTC ATT 
TTA GT-3′) at 10 µM [33]. The cycling conditions were as 
follows: an initial denaturation step at 95 °C for 10 min, 
followed by 45 cycles of denaturation at 95  °C for 30  s, 
primer annealing at 50 °C for 20 s and elongation at 72 °C 
for 1 min.
Results obtained were further categorized into 6 classes 
for the correlation with the LM calculation according 
to a previously published study [1]. Briefly, classes were 
defined based on the cycle threshold (Ct) values: very 
high load (Ct < 20), high load (20.1–24), moderate load 
(24.1–28), low load (28.1–32), very low load (> 32.1), and 
negative results.
16S rDNA amplicon sequencing
Analysis of the LM in all samples was performed for 
each step (DNA extraction, polymerase chain reactions 
(PCRs), sequencing and post sequencing analysis) on a 
single occasion for all samples. As required, strict labo-
ratory controls were done to avoid contaminations from 
PCR reagents and laboratory materials.
DNA was extracted from crude BALFs and PCSs pre-
viously banked at −80  °C, following the protocol pro-
vided with the DNeasy Blood and Tissue kit (QIAGEN 
Benelux BV; Antwerp, Belgium) as already described [29, 
34]. Total DNA quantity and purity were measured after 
extraction using the ND-1000 spectrophotometer (Nan-
oDrop ND-1000, Isogen, De Meern, The Netherlands).
Duplicate qPCRs targeting the V2-V3 region of the 16S 
rDNA were performed to evaluate the bacterial load in 
the lung as already described [29, 35]. qPCRs were con-
ducted in a final volume of 20 µL containing 2.5 μL of 
template DNA, 0.5 μL of forward primer (5′-ACT CCT 
ACG GGA GGC AGC AG-3′; 0.5  μM), 0.5 μL of reverse 
primer (5′-ATT ACC GCG GCT GCTGG-3′; 0.5  μM), 10 
μL of No Rox SYBR 2 × MasterMix (Eurogentec, Seraing, 
Belgium), and 6.5 μL of water. Data were recorded using 
an ABI 7300 real-time PCR system, with the following 
cycling sequence: 1 cycle of 50  °C for 2  min; 1 cycle of 
95 °C for 10 min; 40 cycles of 94 °C for 15 s; and 1 cycle 
of 60  °C for 1 min. A melting curve was constructed in 
the range of 64–99 °C and the end of the cycle. The run 
contained also non-template controls and a tenfold dilu-
tion series of a V2–V3 PCR product purified  (Wizard® 
SV Gel and PCR Clean-Up System, Promega, Leiden, The 
Netherlands), quantified by PicoGreen targeting double-
stranded DNA (Promega) and used to build the stand-
ard curved. The results reflecting the bacterial load were 
expressed in logarithm with base 10 of the copy number 
per milliliter.
To characterize the bacterial populations in samples, 
the V1–V3 region of the bacterial 16S rDNA gene was 
amplified using the forward primer (5′-GAG AGT TTG 
ATY MTGG CTC AG-3′) and the reverse primer (5′-ACC 
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GCG GCT GCT GGCAC-3′) with Illumina overhand 
adapters as previously described [29, 34]. PCRs were 
conducted and amplicons obtained purified with the 
Agencourt AMPure XP beads kit (Beckman Coulter, 
Villepinte, France), indexed using the Nextera XT index 
primers 1 and 2 and quantified by PicoGreen (Ther-
moFisher Scientific, Waltham, MA, USA) before normal-
ization and pooling to form libraries. The amplification 
products < 1 ng/µL were not sequenced.
Sequencing were performed on a Miseq Illumina 
sequencer using V3 reagents with positive controls and 
negative controls from the PCR step.
A total of 3 254 346 reads were obtained after sequenc-
ing with a median length of 510 nucleotides. After a first 
cleaning step, 3 116 730 reads were screened for chimera 
using Vsearch [36]. 3  040  049 reads were retained for 
alignment and clustering using MOTHUR v1.40 [37]. The 
taxonomical assignation with an operational taxonomic 
unit (OTU) clustering distance of 0.03 were based on 
the SILVA database v1.32. A final subsampling was per-
formed with a median reads per samples of 10 000 reads.
Statistical analyses
To compare diseased and healthy dogs, a subpopulation 
of dogs with B. bronchiseptica infection was selected to 
be age-matched with the population of healthy dogs 
(Mann–Whitney tests using XLStat software).
Normality was checked with Shapiro–Wilk tests before 
each comparison between healthy and diseased dogs. 
Mann–Whitney tests were used to compared TCC and 
DCC between diseased and healthy dogs using XLStat 
software. Differences in relative abundances between 
groups at all the taxonomic levels were assessed by 
Welch’s t-tests and Benjamini–Hochberg–false discov-
ery rate of 10% correction [38], with STAMP software. 
The β-diversity was evaluated by a permutational analy-
sis of the variance (PERMANOVA) and visualized with 
a principal component analysis (PCA) using R (R vegan 
package). Other ecological parameters of the LM were 
calculated using MOTHUR v1.40 and compared between 
healthy and diseased dogs with Mann–Whitney tests 
using XLStat software. The α-diversity was based on the 
inverse Simpson index, the richness on the chao index 
and the evenness was derived from the Simpson index. 
The bacterial load was compared between groups with 
Mann–Whitney tests using XLStat software. The bacte-
rial load in PCSs were compared with the corresponding 
bacterial load in BALF samples with a Wilcoxon signed-
rank test using XLStat software.
Correlations between the lung bacterial communities 
at each taxonomic level and the Ct classes for either B. 
bronchiseptica or M. cynos, and the culture results, were 
measured with Spearman tests using XLStat software.
Data were expressed as median and interquartile range. 
A P value < 0.05 was considered as statistically significant.
Results
Animals
Twenty dogs with a diagnosis of B. bronchiseptica infec-
tion and 4 healthy dogs were included in the study 
(Table  1). In all dogs, median age was 9  months (range 
3-18) and medium weight was 11.5  kg (1.3–41.0). From 
the 20 diseased dogs, seven (dogs no. 3, 9, 14, 15, 18, 19 
and 20) were selected and compared with the 4 healthy 
dogs. No significant difference in the age was found 
between the subpopulation of diseased dogs and the 
healthy dogs (P = 0.073). For the TCC, DCC and all LM 
parameters (including relative abundances at all taxo-
nomic levels, the bacterial load and the ecological param-
eters including the β and α-diversity, the richness and 
the evenness), differences between the subpopulations 
of diseased dogs selected or not for the comparison with 
healthy dogs were not significant indicating that the sub-
sampling is representative of all the diseased group (see 
Additional file 1).
French bulldogs, boxers and Cavalier King Charles 
spaniels were among the most represented breeds and 
counted for 50% of the recruited dogs affected with B. 
bronchiseptica. Chronic productive daily cough of at least 
1  week to 4  month’s duration (median of 1  month) was 
reported in all diseased cases. At presentation, 5 dogs 
were receiving oral antimicrobial agents (Table  1) with-
out improvement including amoxicillin/clavulanic acid 
(n = 1), amoxicillin/clavulanic acid with enrofloxacin 
(n = 1), doxycycline (n = 2) and marbofloxacin (n = 1). 
Vaccinal status was recorded for 15 dogs, 6 dogs were 
not vaccinated against B. bronchiseptica and 9 received 
only one subcutaneous vaccinal injection (Pneumo-
dog©, Merial, Lyon, France) between one and 12 months 
(median 2 months) before the development of symptoms. 
Physical examination was normal in 5 dogs, positive 
laryngo-tracheal reflex was noted in 10 dogs, 5 dogs had 
bilateral nasal discharge, 2 had dyspnea and 1 had mild 
hyperthermia (39.1  °C). Thoracic radiography revealed 
the presence of a ventral alveolar pattern in 9 dogs, a 
broncho-interstitial pattern in 8 dogs and no abnormali-
ties in 3 dogs. The diagnosis of B. bronchiseptica infection 
was confirmed by a positive qPCR (n = 9), a positive cul-
ture (n = 1) or both (n = 10).
Bronchoscopy and BALF analysis
During the bronchoscopy procedure, in diseased dogs, 
mucopurulent material was seen in the trachea and bron-
chi in 14 dogs, edema and/or erythema and/or thickening 
of the bronchial wall was noted in 10 dogs, bronchomala-
cia was reported in 4 dogs. TCC and DCC were available 
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in the BALF of 18 and 17 diseased dogs, respectively. 
In all the diseased dogs, median TTC was 1740 cells/
µL (1080–3515) and the median differential cell count 
included 39% (12–63) of macrophages, 41% (24–77) of 
neutrophils, 7% (4–12) of lymphocytes and 1% (0–5) of 
eosinophils.
Compared with healthy dogs, the TTC in the sub-
population of dogs affected with B. bronchiseptica was 
significantly higher with more neutrophils and less mac-
rophages (Table 2).
Culture results
In the diseased dogs, the result of the culture was positive 
for B. bronchiseptica in 6/11 dogs (54.5%) and negative in 
5 dogs from which 4 were under antimicrobial treatment.
B. bronchiseptica and M. cynos quantitative PCR
All qPCR results were positive for B. bronchiseptica in 
the diseased dogs (19/19) and included 1 very high load 
result, 9 high load results, 5 moderate load results and 
2 low load results, one of them corresponding to a dog 
Table 1 Characteristic of the dogs included in the study 
qPCR, quantitative polymerase chain reaction; Ct, cycle threshold value; +, positive result; −, negative result; ?, positive qPCR result but Ct value not known;/, test not 
performed; LOD, only one replicate was above the detection’s limit; SID, once a day; BID, twice a day; PO, oral administration.
Dogs Status Age 
at sampling 
(years)





Ct M. cynos Culture
1 Diseased 0.60 M French bulldog − 28.4 22.9 /
2 Diseased 0.40 M Malamute + (amoxicillin/clavu‑
lanic acid 12.5 mg/kg 
BID and enrofloxacin 
5 mg/kg SID, PO, for 
1 day)
22.3 18.5 −
3 Diseased 1.05 F French bulldog − 25.3 − + (B. bronchiseptica)
4 Diseased 0.43 F Boxer − 21.9 − + (B. bronchiseptica)
5 Diseased 0.65 F French bulldog + (doxycycline 5 mg/kg 
BID, PO, for 10 days)
24.2 LOD + (B. bronchiseptica)
6 Diseased 0.32 F English bulldog + (marbofloxacin 3 mg/
kg SID, PO, for 7 days)
? ? −
7 Diseased 0.35 F Jack Russel terrier − / / + (B. bronchiseptica)
8 Diseased 0.54 M Boxer + (amoxicillin/clavulanic 
acid 12.5 mg/kg BID, 
PO for 1 day)
26.5 24.0 –
9 Diseased 0.99 F Munster lander − 23.6 − + (B. bronchiseptica)
10 Diseased 0.38 F French bulldog − ? / /
11 Diseased 0.56 F Chihuahua − 24.0 ? −
12 Diseased 0.51 F Cavalier king Charles 
spaniel
− 24.0 − + (B. bronchiseptica)
13 Diseased 0.57 F German shepherd − 21.5 LOD + (B. bronchiseptica)
14 Diseased 0.68 F Cavalier king Charles 
spaniel
− 25.6 23.7 + (B. bronchiseptica, Aci-
netobacter baumanii)
15 Diseased 0.99 M Spitz − 17.6 − + (B. bronchiseptica)
16 Diseased 0.53 M Boxer − 25.3 32.8 /
17 Diseased 0.27 M Yorkshire terrier − 21.8 − + (B. bronchiseptica)
18 Diseased 0.90 F Spitz − 23.5 − + (Pantoea agglomerans, 
Serratia marcescens)




20 Diseased 0.72 M Cavalier king Charles 
spaniel
− 21.5 − + (B. bronchiseptica)
21 Healthy 1.26 M Beauceron − − − /
22 Healthy 1.19 M French bulldog − − − /
23 Healthy 1.40 M French bulldog − 38.0 − /
24 Healthy 1.43 M Pug − − − /
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receiving doxycycline. Two qPCRs were positive with-
out information available on the Ct level. qPCR results 
for M. cynos were positive in 7/18 (38.9%) and included 
1 very high load result, 3 high load results and 1 very low 
load result. Two qPCR results were positive but Ct values 
were unknown.
In the healthy group, one dog had a positive qPCR 
result for B. bronchiseptica at a very low load, while the 
results were negative in the 3 other dogs. qPCRs for M. 
cynos were all negative in the healthy group.
Microbiota analysis
The PCSs were not sequenced as their amplification 
products after purification were < 1  ng/µL. An inter-
nal study performed in our laboratory (Taminiau B and 
Daube G, unpublished observations) showed that under 
this value, the sequencing is not reliable. Moreover, the 
bacterial load was about 100 times lower in the PCSs 
compared with the samples (P = 0.016).
B. bronchiseptica was found in each of the 20 diseased 
dogs with a relative abundance of more than 50% in 13 
of them. Only 2 dogs (dogs n°1 and 11) had a relative 
abundance of B. bronchiseptica of less than 5% (Figure 1). 
Among the diseased dogs, 40% (8/20) were co-infected 
with M. cynos and/or Pseudomonas sp. and other strain 
of Mycoplasma than M. cynos. Other bacteria were also 
found in high relative abundance (> 5%) including, Eliza-
bethkingia meningoseptica, Stenotrophomonas sp., Urea-
plasma sp., Alcaligenaceae_genus sp., Elizabethkingia 
Table 2 Total and differential cell counts between the subpopulation of diseased dogs and healthy dogs 
Results are expressed as median (range). Significant P-value are in italic. The subpopulation of diseased dogs corresponds to the dogs no. 3, 9, 14, 15, 18, 19 and 20 in 
the Table 1.
Total cell count (cells/µL) Macrophages (%) Neutrophils (%) Lymphocytes (%) Eosinophils (%)
Subpopulation of dis‑
eased dogs (n = 7)
1300 (1040–3622) 33 (15.8–47.2) 48 (35.8–68.5) 9.5 (6.2–15.8) 2 (1–6.8)
Healthy dogs (n = 4) 270 (243.8–380) 91.5 (85.5–96.2) 2.5 (2–3.2) 6 (0.8–11.2) 0.5 (0–1.5)

















Bordetella bronchiseptica Mycoplasma cynos
Mycoplasma sp. Bordetella sp.
Elizabethkingia meningoseptica Pseudomonas putida
Pseudomonas sp. Alcaligenaceae sp.
Fusobacterium sp. Ureaplasma sp.
Methylotenera sp. Stenotrophomonas sp.
Pseudomonas sp. Escherichia-Shigella sp.
Others (< 0.3 %)
Figure 1 Species-level composition of the lung microbiota in dogs affected with B. bronchiseptica. Bar charts showing relative abundance 
annotated to the taxonomic level of species of all taxa detected in the bronchoalveolar lavage fluid of 20 dogs affected with B. bronchiseptica. 
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meningoseptica, Fusobacterium sp., Methylotenera sp. 
and Escherichia-Shigella sp. (Figure 1).
In healthy dogs, B. bronchiseptica was found by ampli-
con sequencing in one dog and M. cynos in 3 dogs in a 
very low relative abundance (0.43 and 0.55, 0.52 and 
0.61% respectively).
In diseased compared with healthy dogs, a shift was 
observed in the bacterial populations with more Alca-
ligenaceae in diseased compared with healthy dogs 
(82.3% (62.6-99.4) versus 2.2% (1.3–3.8); P-value cor-
rected = 0.058) at the family level (Figure  2B). At the 
genus level (Figure  2C), there were more Bordetella in 
diseased compared with healthy dogs (82.3% (61.7-99.4) 
versus 0% (0–0.1); P-value corrected = 0.11). There was 
no significant difference at the phylum (Figure 2A) and at 
the species levels (Figure 2D), although a marked increase 
in Proteobacteria (94.3% (67.6-99.6) versus 38.9% 
(30.4–49.0); P-value corrected = 0.30) phylum reflect-
ing the increase in B. bronchiseptica (79.8% (59.5–96.2) 
versus 0% (0–0.1); P-value corrected = 0.40) species 
was noted in diseased compared with healthy dogs. The 
β-diversity (Figure  3) assessed by the PERMANOVA 
was significantly different between healthy and diseased 
dogs (P = 0.0024). The α-diversity (Figure 4A) as well as 
the richness (Figure  4B) were significantly lower in dis-
eased compared with healthy dogs. There was no differ-
ence between healthy and diseased dogs for the evenness 
(P = 0.10) ((Figure 4C). Finally, the bacterial load was sig-
nificantly higher in dogs with B. bronchiseptica infection 
compared with healthy dogs (Figure 5).
A significant positive correlation was found between 
the bacterial composition in B. bronchiseptica and M. 
cynos at each taxonomic level obtained by the 16S rDNA 
amplicon sequencing and the Ct classes for B. bron-
chiseptica and M. cynos, and the culture results as shown 
in Table 3. In all cases where a positive culture was found 
for B. bronchiseptica, the relative abundance for B. bron-






































































Bordetella bronchiseptica Mycoplasma cynos
Mycoplasma sp. Pasteurellaceae sp.
Cutibacterium sp. Porphyromonas sp.
Elizabethkingia meningoseptica Pseudomonas sp.
Bordetella sp. Haemophilus haemoglobinophilus
Mycoplasma edwardii Conchiformibius sp.
Neisseria shayeganii Streptococcus sp.
Streptococcus sp. Ureaplasma sp.
Gemella palaticanis Pasteurellaceae sp.






Figure 2 Taxa detected in healthy dogs and dogs affected with B. bronchiseptica. Bar charts showing the relative abundance of all taxa 
detected in the bronchoalveolar lavage fluid of 4 healthy dogs and 7 dogs affected with B. bronchiseptica, annotated to the taxonomic level of 
phylum (A), family (B), genus (C) and species (D).
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2 dogs, other bacteria were identified by culture includ-
ing Acinetobacter baumanii, Pantoea agglomerans and 
Serratia marcescens (Table 1) but were not identified by 
sequencing.
Discussion
In the present study, we described the LM in dogs with 
CIRD-C and B. bronchiseptica infection. We showed a 
clear dysbiosis of the LM with a significant decrease in 
α-diversity and richness, as well as an increased bacte-
rial load, in dogs affected with B. bronchiseptica com-
pared with healthy dogs. The Alcaligenaceae family and 
the Bordetella genus were overrepresented in diseased 
dogs. In the sequencing profile, about half of the dis-
eased dogs were co-infected, the majority with M. cynos. 
Finally, a positive correlation was found between the bac-
terial composition of the LM for B. bronchiseptica and 
M. cynos at each taxonomic level and the corresponding 
qPCR or culture result.
In this study, the major phyla found in healthy dogs 
were the Proteobacteria, the Bacteroïdetes, the Actino-
bacteria and the Firmicutes. The same major phyla have 
already been reported in the LM of healthy dogs [28, 29, 



































Figure 3 Principal component analysis representing the 
β-diversity between healthy dogs and dogs affected with B. 
bronchiseptica. Lung communities are clustered by groups (diseased 







































































Figure 4 Ecological parameters comparison between healthy dogs and dogs affected with B. bronchiseptica. Box plot graphs representing 
the bacterial alpha diversity (A), richness (B) and evenness (C) in healthy (n = 4) compared with diseased dogs (n = 7). The medians are represented 
by the central horizontal bars. The lower and upper limits of the box are the first and third quartiles, respectively. *P = 0.012; **P = 0.006.
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31]. Despite their implication in CIRD-C, B. bronchisep-
tica and M. cynos are commensal bacteria found in the 
respiratory tract of healthy dogs [1, 4, 8]. In the present 
study, the amplicon sequencing technique detected B. 
bronchiseptica at very low level in 1 healthy dog, in which 
qPCR revealed a very low load. The absence of dysbio-
sis associated with the presence of B. bronchiseptica at 
a very low level in that dog, corroborates the fact that 
this bacterium is a commensal bacterium which is not 
always associated with lung disease [1, 4, 8]. The ampli-
con sequencing technique also detected M. cynos in low 
relative abundance in 3 of the healthy dogs, while qPCR 
results were negative. Since different aliquots from a same 
initial sample of BALF were used for qPCR and amplicon 
sequencing technique, a lack of homogeneity between 
the aliquots could explain this slight discrepancy.
Compared with healthy dogs, a dysbiosis was observed 
in the diseased dogs, with a shift in microbial popula-
tions as shown by a clear difference in the β-diversity. 
The Proteobacteria and the Tenericutes phylum were 
more abundant in the diseased dogs, logically reflecting 
an increased prevalence of Bordetella and Mycoplasma. 
The incapacity to show significant differences between 
healthy and diseased dogs at the species level was prob-
ably due to a lack of power in the statistical tests related 
to the low number of control dogs included in the study 
as well as to the high number of data (10 000 sequences 
per sample). Indeed, large dataset requires more severe 
corrections for multiple tests [39]. In dogs affected with 
B. bronchiseptica infection, in comparison with heathy 
dogs, the LM was composed in majority by only one or 
two bacteria, a finding that has also been reported in 
dogs with CAP [30]. In pneumonia in man, the dominant 
pathogenic strain also usually represents the majority of 
the detected sequences (74% or more) [24]; a low alpha-
diversity and low richness reflecting the high predomi-
nance of one or two bacteria are also described together 
with an increased bacterial load [26]. In the present study, 
we observed identical modifications since the α-diversity 




























Figure 5 Bacterial load in healthy dogs and dogs affected 
with B. bronchiseptica. Box plot representing the logarithm of 
the number of 16S rDNA copies per microliter (bacterial load) 
between healthy (n = 4) and diseased dogs (n = 7). The medians are 
represented by the central horizontal bars. The lower and upper limits 
of the box are the first and third quartiles, respectively. *P = 0.004.
Table 3 Correlation between the 16S rDNA amplicon sequencing and either Ct classes or culture 
Significant positive correlation results between the bacterial composition of the LM in all dogs (n = 24) for B. bronchiseptica and M. cynos at each taxonomic level and 
either B. bronchiseptica and M. cynos Ct classes or the culture. qPCR, quantitative polymerase chain reaction; r, Spearman correlation coefficient
16S rDNA amplicon sequencing 
results
B. bronchiseptica M. cynos
qPCR results Culture results qPCR results
r P-value r P-value r P-value
Phyla
 Proteobacteria 0.54 0.012 0.70 0.0022
 Tenericutes 0.66 0.0018
Families
 Alcaligenaceae 0.66 0.0015 0.70 0.0021
 Mycoplasmataceae 0.66 0.0018
Genera
 Bordetella 0.73 < 0.001 0.70 0.0022
 Mycoplasma 0.66 0.0018
Species
 Bordetella_bronchiseptica 0.71 < 0.001 0.70 0.0022
 Mycoplasma_cynos 0.73 < 0.001
 Bordetella_Otu00473 0.70 < 0.001 0.68 0.0017
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load higher in diseased compared with healthy dogs. 
These modifications are supported by the ecological 
modeling of the LM proposed by Dickson et al. [26]. In 
healthy individuals, the bacterial communities found in 
the LM are mainly determined by the balance between 
immigration and elimination while in injured respira-
tory tract, the local growth conditions are altered creat-
ing a pressure across bacterial members and improving 
the reproduction rate of adapted bacteria which results 
in an increase in the bacterial load and a decrease in the 
richness and the diversity, together with the emergence 
of dominating bacteria [26].
The prevalence of bacterial co-infections in dogs 
affected with B. bronchiseptica found in this study by 
sequencing is quite elevated (40%) in comparison with 
data from the literature, where bacterial co-infections 
are reported in 7.69% to 53% of cases [1, 3, 6]. Reported 
co-infecting bacteria in CIRD-C also found in that study 
by sequencing included M. cynos [1], other Mycoplasma 
species [3, 6] and Pseudomonas sp. [8]. Other bacteria 
with a relative abundance > 5% that have been associ-
ated with pneumonia such as Stenotrophomonas sp., 
Ureaplasma sp., Escherichia-Shigella sp. in dogs [5, 30, 
40–42], or Elizabethkingia meningoseptica in man [43] 
were found in that study. Although it is unclear if they 
are just colonizing or co-infecting bacteria, and if they 
could potentially play a role in CIRD-C. The high rate of 
co-infections in this study could be associated with the 
selection of the diseased dogs. Indeed, in CIRD-C, the 
disease is often self-limiting and resolves spontaneously 
within 2 weeks without complications [8] while co-infec-
tions are usually associated with more severe and chronic 
clinical signs [4]. The diseased dogs were referral cases 
with clinical signs for a median duration of 1 month. 
Higher bacterial co-infection rate could also be related to 
underlying viral infection [4, 8], which was not assessed 
in this study.
As previously reported and confirmed in this study, the 
qPCR is a very sensitive technique to diagnose B. bron-
chiseptica infection [1]. All infected dogs tested in this 
study had a positive qPCR result for B. bronchiseptica 
generally at moderate to very high load. The result of the 
culture was negative in 5/11 dogs which could partially 
be related to the fact that four of those dogs had recently 
been treated with antimicrobial drugs which may impair 
culture growth. Negative culture results have also already 
been described in dogs with B. bronchiseptica infection 
and could be associated with the sensitivity of the tech-
nique [1]. In man, it has been shown that the culture 
sensitivity in Bordetella sp. infections was lower than the 
PCR sensitivity [44]. In the present study, B. bronchisep-
tica was found by 16S rDNA amplicon sequencing in 
high amount in all the diseased dogs. The results of the 
amplicon sequencing at each taxonomic level were cor-
related with the Ct classes and the culture results. Such 
good agreement between positive culture results and 16S 
rDNA sequencing results has already been reported [30], 
with a high relative abundance of the taxa found by cul-
ture. Also, as already reported, some ubiquitous bacteria 
identified by culture were not found with the 16S rDNA 
amplicon sequencing which could be due to a mis anno-
tation of the SILVA database or to a contamination of the 
culture which could lead to errors in culture-based anti-
microbial drug selection [30]. Other co-infecting and/
or colonizing bacteria were detected by the sequencing, 
showing that the 16S rDNA amplicon sequencing can be 
an interested technique to identified new potential patho-
gens. Moreover, the sequencing depicts the global bacte-
rial population on the contrary of the qPCR and culture. 
Indeed, the qPCR is specific of the targeted sequence 
and is not useful to detect new bacteria [45]. Culture is 
quite challenging; some bacteria like Mycoplasma sp. 
requires specific culture conditions, some bacteria are 
unculturable and other bacteria are rare and slow grow-
ing and therefore may be missed [20]. The present study 
has some limitations. Firstly, qPCR Ct and culture results 
were not available in all dogs. Moreover, the qPCRs were 
performed on different type of materials (frozen or fresh, 
pellet or crude BALF). Some dogs were treated with anti-
microbial drugs at the time of sampling which could have 
an impact on culture, qPCR and sequencing results. Cul-
ture results of BALF samples from healthy dogs were not 
available. We consider that such results are not essen-
tial since our study focuses on the evaluation of the 16S 
rDNA amplicon sequencing technique in diseased dogs, 
in a clinical context. Besides, we have a quite limited 
number of control dogs and in order to compare age-
matched groups, we have selected a subpopulation of our 
diseased dogs for the comparison. Indeed, although in 
dogs the effect of aging has not been studied, in man, the 
LM has been reported to be different in young children 
of less than 3  years compared with adults [24]. Healthy 
dogs were not breed-matched with the diseased dogs. 
However, the breed impact on the LM seemed to be sub-
tle [31]. No differences between the selection of diseased 
dogs and the rest of the diseased group were shown sug-
gesting that the selection is representative of the diseased 
group.
In dogs with CIRD-C and B. bronchiseptica infec-
tion, there is a major dysbiosis of the LM, characterized 
by high bacterial load, low richness and diversity and 
increased abundance of B. bronchiseptica, in comparison 
with healthy dogs.
Co-infections, mostly with M. cynos, are frequent in 
CIRD-C dogs with B. bronchiseptica infection and could 
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have an impact on the duration of the disease and the 
response to treatment.
The sequencing results highly correlated with results 
obtained by specific qPCR of B. bronchiseptica and M. 
cynos and culture of B. bronchiseptica. Therefore, 16S 
rDNA amplicon sequencing is reliable to identify poten-
tial causal bacterial microorganism involved in lung 
infectious diseases, to understand the global interaction 
between bacteria in the lung and could be useful to iden-
tify new species potentially involved in respiratory dis-
eases in dogs.
In the future, with the development of 16S technolo-
gies, it could be interesting to include those analyses in 
the diagnostic work-up, mostly in dogs with a suspicion 
of lower airway infection, especially when the classi-
cal culture is negative or when there is no or only poor 
response to classical treatment. However, in such case, 
additional culture will still be needed to detect bacterial 
resistance to antimicrobial drugs.
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